Sensei Biotherapeutics (FTH) Stock Forecast & Price Target $20.57 -0.22 (-1.06%) Closing price 10/21/2026 04:00 PM EasternExtended Trading$20.04 -0.53 (-2.58%) As of 10/21/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Sensei Biotherapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating BuyBased on 17 Analyst RatingsSell1Hold1Buy15 Based on 17 Wall Street analysts who have issued ratings for Sensei Biotherapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 17 analysts, 1 has given a sell rating, 1 has given a hold rating, 12 have given a buy rating, and 3 have given a strong buy rating for FTH. Consensus Price Target $56.25173.46% Upside According to the 17 analysts' twelve-month price targets for Sensei Biotherapeutics, the average price target is $56.25. The highest price target for FTH is $70.00, while the lowest price target for FTH is $50.00. The average price target represents a forecasted upside of 173.46% from the current price of $20.57. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for FTH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sensei Biotherapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FTH Analyst Ratings Over TimeTypeCurrent Forecast10/22/25 to 10/22/261 Month Ago9/22/25 to 9/22/263 Months Ago7/24/25 to 7/24/261 Year Ago10/22/24 to 10/22/25Strong Buy3 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy12 Buy rating(s)11 Buy rating(s)6 Buy rating(s)2 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$56.25$56.25$54.00$55.00Forecasted Upside173.46% Upside68.41% Upside90.88% UpsideN/AConsensus RatingBuyModerate BuyModerate BuyModerate Buy FTH Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History FTH Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Sensei Biotherapeutics Stock vs. The CompetitionTypeSensei BiotherapeuticsHealthcare CompaniesBroader MarketConsensus Rating Score 3.00 2.32 2.53Consensus RatingBuyHoldModerate BuyPredicted Upside173.46% Upside1,327.61% Upside16.99% UpsideNews Sentiment RatingPositive NewsSee Recent FTH NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/22/2024 - 10/22/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/16/2026 William Blair3 of 5 starsAlethia YoungNot RatedInitiated CoverageOutperform10/15/2026 Lifesci Capital5 of 5 stars UpgradeStrong-Buy9/16/2026 Guggenheim5 of 5 starsBrad Canino5 of 5 starsInitiated CoverageBuy$70.00+97.91%9/14/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingSell (D-)9/9/2026 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankingsTara BancroftSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy8/21/2026 Needham & Company LLCSubscribe to MarketBeat All Access to unlock brokerage rankingsGil BlumSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy$56.00+74.45%8/11/2026 HC WainwrightSubscribe to MarketBeat All Access to unlock brokerage rankingsPatrick R. TrucchioSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$60.00+110.01%8/4/2026 JonesTradingSubscribe to MarketBeat All Access to unlock brokerage rankingsMatthew MurraySubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy$55.00+130.38%7/31/2026 Raymond James FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsSean McCutcheonSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$56.00+94.31%7/28/2026 OppenheimerSubscribe to MarketBeat All Access to unlock brokerage rankingsJay OlsonSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$60.00+105.20%This free guide explains options the way they should be taught (Ad)Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.Claim your free options guide and start building real trading knowledge7/20/2026 Citizens JmpSubscribe to MarketBeat All Access to unlock brokerage rankingsSilvan TurkcanSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$51.00+97.14%7/16/2026 BTIG ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsJeet MukherjeeSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$55.00+74.77%6/26/2026 Robert W. BairdSubscribe to MarketBeat All Access to unlock brokerage rankingsJack AllenSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$57.00+131.05%6/4/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access to unlock brokerage rankingsLi WatsekSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOverweight5/28/2026 Loop CapitalSubscribe to MarketBeat All Access to unlock brokerage rankingsChristopher LiuSubscribe to MarketBeat All Access to unlock analyst rankingsSet Target$50.00+192.14%5/22/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsSamantha SemenkowSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy$55.00+213.21%4/21/2026 Zacks ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeHold4/20/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankings Initiated CoverageOutperform$50.00+63.99%5/1/2025 StephensSubscribe to MarketBeat All Access to unlock brokerage rankingsSudan LoganathanSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeStrong-BuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:55 AM ET. FTH Forecast - Frequently Asked Questions What is Sensei Biotherapeutics' forecast for 2026? According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Sensei Biotherapeutics is $56.25, with a high forecast of $70.00 and a low forecast of $50.00. Should I buy or sell Sensei Biotherapeutics stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last year. There is currently 1 sell rating, 1 hold rating, 12 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FTH shares. Does Sensei Biotherapeutics's stock price have much upside? According to analysts, Sensei Biotherapeutics's stock has a predicted upside of 173.46% based on their 12-month stock forecasts. Has Sensei Biotherapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, Sensei Biotherapeutics's stock had 2 upgrades by analysts. What analysts cover Sensei Biotherapeutics? Sensei Biotherapeutics has been rated by research analysts at Guggenheim, HC Wainwright, JonesTrading, Lifesci Capital, Needham & Company LLC, Oppenheimer, Raymond James Financial, TD Cowen, Weiss Ratings, and William Blair in the past 90 days. Do Wall Street analysts like Sensei Biotherapeutics more than its competitors? Analysts like Sensei Biotherapeutics more than other "healthcare" companies. The consensus rating for Sensei Biotherapeutics is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how FTH compares to other companies. Stock Forecasts and Research Tools Related Companies IRON Stock Forecast CLDX Stock Forecast NRIX Stock Forecast ADMA Stock Forecast AUPH Stock Forecast IMNM Stock Forecast RXRX Stock Forecast BCRX Stock Forecast NVAX Stock Forecast VCEL Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Sensei Biotherapeutics RecommendationsWilliam BlairLifesci CapitalWall Street ZenGuggenheimWeiss RatingsTD CowenNeedham & Company LLCHC WainwrightJonesTradingRaymond James FinancialOppenheimerCitizens JmpBTIG ResearchRobert W. BairdCantor Fitzgerald MarketBeat monitors more than a dozen sources for Sensei Biotherapeutics analyst ratings, with the most recent rating issued on 10/16/2026. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
